🟢 Standard Biotools is trading 5% up today after Microfluidics sale agreement with ARCHIMED

Standard Biotools is trading at $0.80, up 5.06%, following its October 5 announcement of an agreement to sell its Microfluidics business to ARCHIMED.

• The sale is expected to close in approximately 30 days, subject to customary conditions; financial terms were not disclosed.
• Shares closed at $0.76 on October 5, according to the provided price context.
• The transaction is the clearest identified catalyst for the October 6 gain; available reporting identifies no separate October 6 announcement.